← Back to Analyst Consensus 
IKT Buy
Inhibikase Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Next Earnings
Nov 12, 2026 (17 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 13, 2026 | Chardan Capital | initiate | — → Neutral | — | 47% |
| Jun 10, 2026 | Oppenheimer | initiate | — → Outperform | — | 52% |
| Mar 4, 2026 | Ladenburg Thalmann | initiate | — → Buy | — | 45% |
| Jan 21, 2026 | B of A Securities | initiate | — → Buy | $6 | 53% |
| Dec 17, 2025 | Freedom Broker | initiate | — → Buy | — | 59% |
| Dec 11, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $4 | 50% |
| Mar 28, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $0 | 44% |
| Feb 12, 2025 | HC Wainwright & Co. | downgrade | Buy → Neutral | $0 | 44% |
| Nov 8, 2024 | Jefferies | initiate | — → Buy | $8 | 52% |
| Oct 14, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $5 | 44% |
| Aug 16, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $15 | 44% |
| May 21, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $23 | 44% |
| Mar 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $27 | 44% |
| Mar 5, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $27 | 44% |
| Aug 15, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $27 | 44% |
| Jun 30, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $27 | 44% |
Price Target Trend
Apr 7, 2026 Latest: $5.55 Oct 25, 2026
EPS Estimates
0q $-0.13
Lo: $-0.16 Hi: $-0.11
4 analysts +1q $-0.13
Lo: $-0.16 Hi: $-0.11
4 analysts 0y $-0.40
Lo: $-0.45 Hi: $-0.33
5 analysts +1y $-0.42
Lo: $-0.48 Hi: $-0.37
5 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days